CompletedNot applicableNCT02981979

Takayasu Arteritis Clinical Trial in China

Studying Takayasu arteritis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Jiang lindi
Principal Investigator: Lindi Jiang, Doctor, PA-C
Fudan University
Intervention: Leflunomide(LEF)(drug)
Enrollment: 116 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2016 – 2022

Study locations (6)

Beijing Anzhen Hospital, Beijing, Beijing Municipality, China
The first affiliated hospital of Nanchang University, Nanchang, Jiangxi, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Zhongshan hospital, Fudan University, Shanghai, Shanghai Municipality, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Ürümqi, Xinjiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02981979 on ClinicalTrials.gov

Other trials for Takayasu arteritis

Additional recruiting or active studies for the same condition.

See all trials for Takayasu arteritis →

← Back to all trials